Veralipride
From Infogalactic: the planetary knowledge core
![]() |
|
![]() |
|
Systematic (IUPAC) name | |
---|---|
2,3-dimethoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide
|
|
Clinical data | |
Trade names | Agreal, Agradil |
Legal status |
|
Routes of administration |
Oral |
Identifiers | |
CAS Number | 66644-81-3 ![]() |
ATC code | N05AL06 (WHO) |
PubChem | CID: 47979 |
ChemSpider | 43638 ![]() |
UNII | S7064109UD ![]() |
Chemical data | |
Formula | C17H25N3O5S |
Molecular mass | 383.4625 g/mol |
|
|
|
|
![]() ![]() |
Veralipride (Agreal, Agradil) is a benzamide neuroleptic medicine indicated in the treatment of vasomotor symptoms associated with the menopause. It was first authorised for use in 1979. Veralipride has never gained approval in the United States.
In September 2006, it was withdrawn from the Spanish market. As a result, the European Commission referred the matter to the European Medicines Agency (EMA). On July 2007, the EMA recommended the withdrawal of marketing authorisations for veralipride.[1]
See also
References
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Drugs with non-standard legal status
- Chemical articles having calculated molecular weight overwritten
- Articles with changed InChI identifier
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Alkenes
- Benzamides
- Pyrrolidines
- Sulfonamides
- Withdrawn drugs
- Typical antipsychotics
- Nervous system drug stubs